VGI Health Technology Limited (NSX:VTL) is an Australian public listed biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.
VGI Health Technology Limited
NSX:VTL ISIN:AU0000152597
News
VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd, has commenced recruitment of patients for its Phase II clinical study in Non-Alcoholic Fatty Liver Disease/Non-Alcoholic SteatoHepatitis.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that it has today executed a binding agreement for the sale of its wholly owned subsidiary Invictus BioPharma Pty Ltd.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that the United States Patent and Trademarks Office (USPTO) intends to grant a divisional patent for the 'Transmucosal Delivery of Tocotrienols' to its wholly-owned subsidiary Invictus Biotechnology Pty Ltd.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that Dr Jordan Moon, a member of its Scientific Advisory Board, will be presenting an abstract at the American Society for Nutrition (ASN) Annual Conference, Nutrition 2022.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly-owned US subsidiary, Invictus Nutraceuticals, Inc. (IVN), has executed a Sales Representative Agreement with Continuum Sciences LLC of Colorado.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that Dr Jordan Moon, a member of its Scientific Advisory Board, will be presenting two abstracts at the American Physiological Society's (APS) Annual Meeting Experimental Biology Conference 2022 in Philadelphia, USA.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that it has executed a non-binding Term Sheet for the sale of its wholly owned subsidiary, the Invictus BioPharma Pty Ltd Group to Invictus BioPharma Holdings Ltd.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly-owned subsidiary, Invictus Ops Pty Ltd, has received Human Research Ethics Committee (HREC) approval from a Lead Ethics Committee Site, Bellberry Ltd, for a Phase II clinical study on Non-Alcoholic Fatty Liver Disease.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that the Hong Kong Patent Office has granted a patent for the Transmucosal Delivery of Tocotrienols to its wholly-owned subsidiary, Invictus Biotechnology Pty Ltd.
Invictus Ops Pty Ltd, a wholly owned subsidiary of NSX-listed VGI Health Technology Limited (NSX:VTL), is pleased to announce that it has contracted Resonance Health Ltd (ASX:RHT) to provide liver-fat quantification services for its clinical study on a potential new treatment for Non-Alcoholic Steatohepatitis.
92,792 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 158) (Last 30 Days: 508) (Since Published: 90902)